GlassScriptPhysician profile
Allyson B Williams
NPI 1407115579
$5,525.27
in general payments reported to CMS, 2019-2025
28 companies · $840 in 2025
The $840 reported for 2025 was more than what 77% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $713 · 2022: $581 · 2023: $1,673 · 2024: $1,719 · 2025: $840.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,220 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,219.67 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,045.30 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $805.51 | 2022-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $500.33 | 2022-2024 | Caplyta |
| Alkermes, INC. | $446.78 | 2021-2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $391.85 | 2021-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $389.08 | 2021-2025 | Rexulti, Nuedexta |
| Takeda Pharmaceuticals U.S.A., INC. | $290.00 | 2021-2025 | Trintellix |
| Lundbeck LLC | $233.98 | 2021-2025 | Rexulti, Abilify Maintena |
| Tris Pharma INC | $206.19 | 2023-2025 | Dyanavel Xr |
| Janssen Pharmaceuticals, INC | $205.73 | 2021-2025 | Invega Sustenna, Spravato |
| Bausch Health US, LLC | $192.61 | 2021-2023 | Aplenzin |
| Neurocrine Biosciences, INC. | $134.27 | 2021-2025 | Ingrezza |
| Ironshore Pharmaceuticals INC. | $103.83 | 2021-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $78.63 | 2023 | Qelbree |
| Sunovion Pharmaceuticals INC. | $74.27 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $62.49 | 2024-2025 | |
| Noven Therapeutics, LLC | $56.79 | 2021-2024 | Xelstrym, Secuado |
| Corium, LLC | $44.26 | 2024 | Azstarys |
| Avanir Pharmaceuticals, INC. | $44.22 | 2022 | |
| Novo Nordisk INC | $41.93 | 2023-2024 | Wegovy |
| Merck Sharp & Dohme LLC | $35.85 | 2021 | |
| Indivior INC. | $31.43 | 2023 | Perseris |
| Biogen, INC. | $22.83 | 2023 | |
| Lilly USA, LLC | $20.65 | 2024 | Zepbound |
| Axsome Therapeutics, INC. | $18.83 | 2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $17.33 | 2025 | Cobenfy |
| Eisai INC. | $15.82 | 2021 | |
| Idorsia Pharmaceuticals US INC | $14.48 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allyson Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.